

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
20 October 2005 (20.10.2005)

PCT

(10) International Publication Number
WO 2005/097206 A3(51) International Patent Classification⁷: A01N 43/04, C12N 15/00

(74) Agents: LEVY, Seth, D. et al.; Suite 2400, 865 South Figueroa Street, Los Angeles, California 90017-2566 (US).

(21) International Application Number: PCT/US2005/011466

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 5 April 2005 (05.04.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/559,990 6 April 2004 (06.04.2004) US

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants (for all designated States except US): CEDARS-SINAI MEDICAL CENTER [US/US]; 8700 Beverly Boulevard, Los Angeles, California 90048 (US). CITY OF HOPE [US/US]; 1500 East Duarte Road, Duarte, California 91010 (US).


Published:

— with international search report

(88) Date of publication of the international search report: 6 April 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PREVENTION AND TREATMENT OF VASCULAR DISEASE WITH RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS ENCODING APOLIPOPROTEIN A-I AND APOLIPOPROTEIN A-I MILANO



(57) Abstract: Described herein is a gene therapeutic approach to the prevention and treatment of vascular disease and coronary heart disease; in particular, atherosclerosis. The inventive methods may be used in the prevention and treatment of atherosclerosis, as well as any disease or physiological condition in which atherosclerosis plays a role. The inventive methods involve the gene delivery of ApoA-I or ApoA-IMilano. This may be accomplished by the use of rAAV technology. rAAV virions may be delivered to a mammalian subject by various methodologies, including transplantation of transduced bone marrow cells, direct intramuscular injection, intravenous or portal vein injection or stent delivery.

WO 2005/097206 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US05/11466

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A01N 43/04; C12N 15/00
US CL : 514/44; 435/320.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/44; 435/320.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	SHARIF et al. AAV serotype-dependent apolipoprotein A-I Milano gene expression. Atherosclerosis. August 2005, Vol. 181, No. 2, pages 261-269.	1-35
X	PASTORE et al. Helper-dependent adenoviral vector-mediated long-term expression of human apolipoprotein A-I reduces atherosclerosis in apo E-deficient mice. Gene. March 2004, Vol. 327, No. 2, pages 153-160.	1, 3, 8, 10-13, 15-17, 19-31, 35

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:		"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

12 December 2005 (12.12.2005)

Date of mailing of the international search report

29 DEC 2005

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (571) 273-3201

Authorized officer

Janet L. Epps-Ford

J. Roberts for

Telephone No. (571) 272-0500

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US05/11466

Continuation of B. FIELDS SEARCHED Item 3:
CAPlus, Medline, USPAT, EPO, JPO, Derwent
search terms: apolipoprotein A1, A1 milano, adenoviral vector.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 October 2005 (20.10.2005)

PCT

(10) International Publication Number
WO 2005/097206 A2

(51) International Patent Classification⁷: A61K 48/00

(21) International Application Number: PCT/US2005/011466

(22) International Filing Date: 5 April 2005 (05.04.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/559,990 6 April 2004 (06.04.2004) US

(71) Applicants (for all designated States except US): CEDARS-SINAI MEDICAL CENTER [US/US]; 8700 Beverly Boulevard, Los Angeles, California 90048 (US). CITY OF HOPE [US/US]; 1500 East Duarte Road, Duarte, California 91010 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SHAH, Prediman, K. [IN/US]; 111 North Layton Drive, Los Angeles, California 90025 (US). CHATTERJEE, Saswati [CA/US]; 678 West Alegria Avenue, Sierra Madre, California 91024 (US). WONG, Kamehameha, Kay-Min, Jr [US/US]; 678 West Alegria Avenue, Sierra Madre, California 91024 (US).

(74) Agents: LEVY, Seth, D. et al.; Suite 2400, 865 South Figueroa Street, Los Angeles, California 90017-2566 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PREVENTION AND TREATMENT OF VASCULAR DISEASE WITH RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS ENCODING APOLIPOPROTEIN A-I AND APOLIPOPROTEIN A-I MILANO



WO 2005/097206 A2

(57) Abstract: Described herein is a gene therapeutic approach to the prevention and treatment of vascular disease and coronary heart disease; in particular, atherosclerosis. The inventive methods may be used in the prevention and treatment of atherosclerosis, as well as any disease or physiological condition in which atherosclerosis plays a role. The inventive methods involve the gene delivery of ApoA-I or ApoA-IMilano. This may be accomplished by the use of rAAV technology. rAAV virions may be delivered to a mammalian subject by various methodologies, including transplantation of transduced bone marrow cells, direct intramuscular injection, intravenous or portal vein injection or stent delivery.

**PREVENTION AND TREATMENT OF VASCULAR DISEASE WITH RECOMBINANT
ADENO-ASSOCIATED VIRUS VECTORS ENCODING APOLIPOPROTEIN A-I AND
APOLIPOPROTEIN A-I MILANO**

GOVERNMENT RIGHTS

5 The U.S. Government has certain rights in this invention pursuant to Grant No. HL-60898 awarded by the National Heart, Lung and Blood Institute.

FIELD OF THE INVENTION

The invention relates to the treatment of vascular disease, and, more particularly, to the treatment of vascular disease with Apolipoprotein A-I ("ApoA-I") or 10 ApoA-I_{Milano}.

BACKGROUND OF THE INVENTION

Coronary heart disease is the leading cause of death in the U.S., and the leading cause of death associated with smoking. Smoking poses a significant, detrimental impact on the heart, and the toxins in cigarette smoke cause plaques to form in the 15 arteries, which oftentimes leads to atherosclerosis. Atherosclerosis is just one of several types of arteriosclerosis, which is characterized by thickening and hardening of artery walls (e.g., coronary arteries, carotid arteries, aorta, ileofemoral arteries). Over time, this material thickens, hardens and may eventually block or severely narrow the arteries. More than 61 million Americans suffer from some form of cardiovascular 20 disease, including high blood pressure, coronary heart disease, stroke, congestive heart failure, and other conditions. More than 2,600 Americans die every day because of cardiovascular diseases; about 1 death every 33 seconds.

ApoA-I, a major component of high density lipoprotein ("HDL"), has been shown to have anti-atherogenic properties. Apolipoprotein A-I_{Milano} ("ApoA-I_{Milano}") is a mutant 25 form of ApoA-I with a single amino acid substitution (Arg₁₇₃ to Cys₁₇₃) (Weisgraber, K.H. *et al.*, "A-I_{Milano} apoprotein, isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins," *J Clin Invest*, Vol. 66, pp. 901-7 (1980)). This mutation appears to confer greater resistance to atherosclerosis in individuals with this genotype (Franceschini, G. *et al.*, "A-I_{Milano} 30 apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family," *J Clin*

Invest, Vol. 66, pp. 892–900 (1980)). The structural alteration of ApoA-I_{Milano} is associated with a higher kinetic affinity for lipids and an easier dissociation from lipid protein complexes, which contributes to its accelerated catabolism and increased uptake of tissue lipids (Franceschini, G. *et al.*, "Apolipoprotein A-I_{Milano}. Accelerated binding and dissociation from lipids of a human apolipoprotein variant," *J Biol Chem*, Vol. 260, pp. 16321–5 (1985)). ApoA-I serves an anti-atherogenic role by functioning to reverse cholesterol transport, reduce oxidized lipids within HDL, prevent foam cell formation, inhibit platelet activation, as well as having anti-inflammatory, anti-oxidant and anti-thrombotic effects. However, the exact mechanism by which ApoA-I_{Milano} confers its resistance to atherosclerosis remains to be elucidated.

It has previously been reported that 5 intravenous injections of recombinant apo A-I milano reduces high cholesterol and balloon injury induced ileofemoral atherosclerosis in rabbits (Ameli, S. *et al.*, "Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits," *Circulation*, Vol. 90, pp. 1930-1941 (1994); in addition repeated intravenous injections of a 40-80 mg/kg dose of recombinant ApoA-I_{Milano} (rApoA-I_{Milano}) over a 5-week period induces a significant reduction/regression in aortic atherosclerosis in ApoE-deficient mice compared with untreated controls (Shah, P.K. *et al.*, "Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice," *Circulation*, Vol. 97, pp. 780–5 (1998)). Furthermore, a single large intravenous dose of recombinant Apo A-I milano was shown to reduce lipid content and inflammation in aortic sinus plaques of ApoE knockout mice within 48 hours leading to a more stable plaque phenotype (Shah, P.K. *et al.*, "High-Dose Recombinant Apolipoprotein A-I_{Milano} Mobilizes Tissue Cholesterol and Rapidly Reduces Plaque Lipid and Macrophage Content in Apolipoprotein E–Deficient Mice: Potential Implications for Acute Plaque Stabilization," *Circulation*, Vol. 103, pp. 3047-3050 (2001). Additional studies using rApo A-I milano have also demonstrated its ability to improve endothelial dysfunction in ApoE knockout mice and reduce in stent stenosis in a porcine model when applied at the site of stent implantation (Kaul, S. *et al.*, "Intramural Delivery of Recombinant Apolipoprotein A-I_{Milano}/Phospholipid Complex (ETC-216) Inhibits In-Stent Stenosis in Porcine Coronary Arteries," *Circulation*, Vol. 107, pp. 2551-2554 (2003); Kaul, S. *et al.*, "Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-I-phospholipid complex," *J Am Coll of Cardiology*, Vol. 44, Issue 6, pp. 1311-1319 (2004). In a more recent double-blind,

randomized, placebo-controlled study, it was demonstrated that infusion of recombinant ApoA-I_{Milano}-phospholipid complexes in patients with acute coronary syndromes with five doses at weekly intervals produced significant regression of the coronary atheroma burden (Nissen, S.E. *et al.*, "Effect of recombinant ApoA-I Milano on coronary 5 atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial," *JAMA*, Vol. 290, pp. 2292-300 (2003)). These findings suggest that therapy based on ApoA-I_{Milano} could have potential as an effective anti-atherogenic strategy. However, frequent intravenous injections and expenses related to the production of recombinant proteins limit the practical and widespread applicability of this approach in 10 humans.

Gene delivery is a promising method for the treatment of acquired and inherited diseases. A number of viral-based systems for gene transfer purposes have been described, such as retroviral systems, which are currently the most widely used viral vector systems for gene transfer. For descriptions of various retroviral systems, see, 15 e.g., U.S. Patent No. 5,219,740; Miller and Rosman (1989) *BioTechniques* 7:980-990; Miller, A.D. (1990) *Human Gene Therapy* 1:5-14; Scarpa *et al.* (1991) *Virology* 180:849-852; Burns *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90:8033-8037; and Boris-Lawrie and Temin (1993) *Cur. Opin. Genet. Develop.* 3:102-109. However, the recent 20 description of retrovirus vector-associated leukemogenesis in two patients has underscored potential limitations of this vector system.

A number of adenovirus-based gene delivery systems have also been developed. Human adenoviruses are double-stranded DNA viruses which enter cells by receptor-mediated endocytosis. These viruses are particularly well suited for gene transfer because they are easy to grow and manipulate and they exhibit a broad host 25 range both *in vivo* and *in vitro*. Adenovirus is easily produced at high titers and is stable so that it can be purified and stored. For descriptions of various adenovirus-based gene delivery systems, see, e.g., Haj-Ahmad and Graham (1986) *J. Virol.* 57:267-274; Bett *et al.* (1993) *J. Virol.* 67:5911-5921; Mittereder *et al.* (1994) *Human Gene Therapy* 5:717-729; Seth *et al.* (1994) *J. Virol.* 68:933-940; Barr *et al.* (1994) *Gene Therapy* 30 1:51-58; Berkner, K.L. (1988) *BioTechniques* 6:616-629; and Rich *et al.* (1993) *Human Gene Therapy* 4:461-476. However adenovirus virus vectors, including the newer helper-dependant adenovirus vectors are associated with triggering host innate immunity that can be highly toxic.

In an earlier study that utilized a recombinant human ApoA-I adenovirus, De Geest *et al.* demonstrated transient expression of wild-type human ApoA-I in ApoE-deficient mice of over 150 mg/dl peaking at 6 days (De Geest, B. *et al.*, "Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after 5 endothelial denudation in apo E-deficient mice," *Circulation*, Vol. 96, pp. 4349–56 (1997)). In a similar study, Tsukamoto *et al.* showed that intravenous injection into ApoE-deficient, low density lipoprotein receptor-deficient and wild-type C57BL/6 mice resulted in mean peak plasma human ApoA-I concentrations of 235, 324 and 276 mg/dl, respectively, after 3 days post-injection and declined thereafter (Tsukamoto, K. 10 *et al.*, "Comparison of human apoA-I expression in mouse models of atherosclerosis after gene transfer using a second generation adenovirus," *J Lipid Res*, Vol. 38. pp. 1869–76 (1997)). The overall decrease in levels of human ApoA-I transgene expression may be attributed to an inflammatory response to virally infected cells (Engelhardt, J.F. *et al.*, "Ablation of E2A in recombinant adenoviruses improves 15 transgene persistence and decreases inflammatory response in mouse liver," *Proc Natl Acad Sci USA*, Vol. 91, pp. 6196–200 (1994)). In another study, gene transfer with an adenovirus and the 256-bp ApoA-I promoter, the genomic ApoA-I DNA, and four ApoE enhancers resulted in ApoA-I expression above 20 mg/dl for up to 6 months (De Geest, B. *et al.*, "Sustained expression of human apolipoprotein A-I after adenoviral gene 20 transfer in C57BL/6 mice: role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancer," *Hum Gene Ther*, Vol. 11, pp. 101–12 (2000)). However, there is no data with regards to the effective concentration of circulating ApoA-I_{Milano}. Rather, past studies have suggested that the circulating levels of serum proteins do not necessarily correlate with their effective biological concentration. For 25 example, bone marrow transplantation studies using ApoE^{+/+} donor and ApoE^{-/-} recipient mice showed significant improvements in atherosclerotic lesions in recipient mice with 10% chimerism (Sakai, Y. *et al.*, "Bone marrow chimerism prevents atherosclerosis in arterial walls of mice deficient in apolipoprotein E," *Atherosclerosis*, Vol. 161, pp. 27–34 (2002)). Other investigators have also examined the effect of 30 macrophage-derived ApoE by bone marrow transplantation with wild-type marrow (Linton, M.F. *et al.*, "Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation," *Science*, Vol. 267, pp. 1034-7 (1995); Boisvert, W.A. *et al.*, "Treatment of severe hyper-cholesterolemia in apolipoprotein E-deficient mice by bone marrow transplantation," *J Clin Invest*, Vol. 96, pp. 1118–24 (1995); Van Eck, M.

et al., "Bone marrow transplantation in apolipoprotein E-deficient mice. Effect of ApoE gene dosage on serum lipid concentrations, (beta)VLDL catabolism, and atherosclerosis," *Arterioscler Thromb Vasc Biol*, Vol. 17, pp. 3117-26 (1997)). These studies demonstrated normalization of plasma cholesterol 4-5 weeks post-transplant and reduction of atherosclerosis 14-20 weeks post-transplant. The level of circulating ApoE varied from 3.8% to 12.5% of normal levels in C57BL/6 mice (Linton, M.F. et al. (1995); Van Eck, M. et al. (1997); Spangenberg, J. et al., "Influence of macrophage-derived apolipoprotein E on plasma lipoprotein distribution of apolipoprotein A-I in apolipoprotein E-deficient mice," *Biochim Biophys Acta*, Vol. 1349, pp. 109-21 (1997)).

10 Therefore, considerably lower levels of the circulating bioactive serum molecules may be sufficient for an effective biological action on the vessel wall.

In a recent study, Van Linthout et al. used a "gutted" helper-virus independent adenoviral vector and an expression cassette consisting of the human $\alpha 1$ -antitrypsin promoter, the human genomic ApoA-I DNA and four copies of the human ApoE enhancer in an effort to improve duration of ApoA-I transgene expression (Van Linthout, S. et al., "Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector," *Gene Ther*, Vol. 9, pp. 1520-8 (2002)). The investigators were able to produce long-term and high levels of ApoA-I expression (170 ± 16 mg/dl at 6 months) in C57BL/6 mice. However, there are still some concerns of toxicity in using these adenoviral vectors in humans (St George, J.A., "Gene therapy progress and prospects: adenoviral vectors," *Gene Ther*, Vol. 10, pp. 1135-41 (2003)). In the case of AAV vectors, the parental wild-type AAV is non-pathogenic (Muzyczka, N., "Use of adeno-associated virus as a general transduction vector for mammalian cells," *Curr Top Microbiol Immunol*, Vol. 158, pp. 97-129 (1992)).

25 The construction of recombinant adeno-associated virus ("rAAV") vectors has been described. See, e.g., U.S. Patent Nos. 5,173,414 and 5,139,941; International Patent Publication Numbers WO 92/01070 (published Jan. 23, 1992) and WO 93/03769 (published Mar. 4, 1993); Lebkowski et al. (1988) *Molec. Cell. Biol.* 8:3988-3996; Vincent et al. (1990) *Vaccines* 90 (Cold Spring Harbor Laboratory Press); Carter, B.J. (1992) *Current Opinion in Biotechnology* 3:533-539; Muzyczka, N. (1992) *Current Topics in Microbiol. and Immunol.* 158:97-129; and Kotin, R.M. (1994) *Human Gene Therapy* 5:793-801; Gao, G. (2002) *Proc Natl Acad Sci USA* 99:11854-11859; Hauck, B. (2003) *Journal of Virology* 77(4):2768-2774; Gao, G. (2004) *Journal of Virology* 78(12):6381-6388.

Eukaryotic vectors based upon the nonpathogenic parvovirus, adeno-associated virus ("AAV"), have recently emerged as promising vehicles for efficient gene transfer. AAV is a replication-defective DNA virus with a 4.7 kb genome with palindromic inverted terminal repeats ("ITR"). Coinfection with a helper virus, typically adenovirus or herpes simplex virus, is required for productive infection. In the absence of helper virus coinfection, AAV stably integrates via the ITRs into chromosomal DNA, or may persist in an episomal state. Wild type AAV is unique in the capacity for integration into a specific region of human DNA termed "AAVS1" on human chromosome 19. AAV have been found in many animal species, including nonhuman primates, canines, fowl, and humans (Murphy, F. A. *et al.*, "Classification and nomenclature of viruses: sixth report of the International Committee on Taxonomy of Viruses," *Arch. Virol.*, Vol. 1995, pp. 169-175 (1995)). There are more than 100 serotypes of AAV, including AAV type 1 (AAV-1), isolated from primates, AAV-2, AAV-3, and AAV-5, isolated from humans, and AAV-6, isolated from a human adenovirus preparation; other serotypes are being intensively evaluated for use in gene therapy. See, e.g. Gao, P. (2004) *J Virol.* ;78(12):6381-6388. AAV-2 is the most characterized primate serotype, since its infectious clone was the first one made (Samulski, R. J. *et al.*, "Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells," *Proc. Natl. Acad. Sci. USA*, Vol. 79, pp. 2077-2081 (1982)). The full sequences for AAV-3A, AAV-3B, AAV-4, and AAV-6 recently were determined (Chiorini, J.A. *et al.*, "Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles," *J. Virol.*, Vol. 71, pp. 6823-6833 (1997); Muramatsu, S. *et al.*, "Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3," *Virology*, Vol. 221, pp. 208-217 (1996); Rutledge, E.A. *et al.*, "Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2," *J. Virol.*, Vol. 72, pp. 309-319 (1998)). Generally, all primate AAV show more than 80% homology in nucleotide sequence. AAV vectors have been based primarily on serotype 2, a human-derived parvovirus (Parks, W.P. *et al.*, "Seroepidemiological and ecological studies of the adenovirus-associated satellite viruses," *J. Virol.*, Vol. 2, pp. 716-722 (1970); Samulski, R. J., "Adeno-associated virus: integration at a specific chromosomal locus," *Curr. Opin. Genet. Dev.*, Vol. 3, pp. 74-80 (1993)). The early availability of an infectious clone of AAV-2 stimulated work on the development of replication-defective vectors. The AAV2 genome has two major open reading frames ("ORFs"); the left encodes functions necessary for AAV ori mediated replication and site

specific integration (*Rep*), while the right encodes functions necessary for encapsidation (*Cap*). AAV vectors transduce many different types of cells. Multiple studies have amply demonstrated that rAAV vectors can transduce quiescent, nonproliferating targets. rAAV vectors do not encode any viral encoded genes, 5 reducing their intrinsic immunogenicity. In addition, prolonged *in vivo* transgene expression following rAAV transduction has been documented in animal models. Finally, since its discovery in the mid-1960s, wild type AAV has yet to be definitively identified as a pathogen in either animals or humans. On the contrary, there is evidence that infection with wild type AAV inhibits transformation by bovine and human 10 papillomaviruses and the activated H-ras oncogene *in vitro*, and induces apoptosis in p53 deficient, malignant cells, while epidemiologic studies suggest that prior infection in humans may actually confer an oncoprotective effect. Thus, for reasons outlined above and supported by data described herein, AAV-based vectors are well suited for the stable introduction of transgenes into hematopoietic cells.

15 Thus, there is a need in the art for a gene therapy strategy for the treatment of atherosclerosis and the array of diseases and physiological conditions related to the same. It is likely that the use of rAAV vectors would be virtually harmless for *in vivo* gene transfer, and may offer a viable approach for elevated and sustained levels of ApoA-I_{Milano} expression. Therefore, a strategy for gene delivery and expression, which 20 would result in constitutive and persistent levels of circulating ApoA-I and/or ApoA-I_{Milano} protein, particularly when delivered via rAAV vector technology, is especially desirable.

SUMMARY OF THE INVENTION

Described herein are compositions and methods for inhibiting atherosclerosis. The composition and method include providing a recombinant adeno-associated viral 25 (rAAV) vector and delivering the rAAV vector to a mammal. The invention further includes transducing the rAAV vector encoding the Apolipoprotein A-I (ApoA-I) or ApoA-I_{Milano}. The invention includes a purified rAAV vector encoding ApoA-I or ApoA-I_{Milano}, and a host cell genetically modified with rAAV-ApoA1 or rAAV-ApoA1 milano.

30 In another embodiment of the invention, the rAAV-ApoA-I or rAAV-ApoA-I_{Milano} vector is first transduced into multipotent stem cells. The invention further includes transplanting the multipotent stem cells in a mammal. The multipotent stem cells may be bone marrow, cord blood or cytokine-primed peripheral blood cells.

In other embodiments of the invention, a kit is included with the rAAV vector of the invention and instructions for its use in the treatment of atherosclerosis in a mammal.

BRIEF DESCRIPTION OF THE FIGURES

5 **FIGURE 1** shows the supernatant ApoA-I levels following intramuscular injection of ApoE-/- mice with rAAV2-ApoA-I_{Milano} vectors in accordance with an embodiment of the invention.

10 **FIGURE 2** shows the body weight of ApoE-/- mice following intramuscular injection for control, rAAV, rAAV2-ApoA-I_{Milano} and rAAV5-ApoA-I_{Milano} vector treatments in accordance with an embodiment of the invention.

FIGURE 3 shows the plasma cholesterol levels of ApoE-/- mice following intramuscular injection for control, rAAV, rAAV2-ApoA-I_{Milano} and rAAV5-ApoA-I_{Milano} vector treatments in accordance with an embodiment of the invention.

15 **FIGURE 4** shows no difference in body weight (FIGURE 4A) or plasma cholesterol level (FIGURE 4B) with intramuscular rAAV2-ApoA-I_{Milano} gene transfer in accordance with an embodiment of the invention.

FIGURE 5 shows the effect of intramuscular rAAV2-ApoA-I_{Milano} gene transfer on native aortic atherosclerosis in accordance with an embodiment of the invention.

20 **FIGURE 5A** depicts photographs of excised aortic samples of PBS, control vector and rAAV2-ApoA-I_{Milano} treated mice. **FIGURE 5B** shows the relative percentage of plaque in aortic samples for the photographs in Figure 5A.

FIGURE 6 shows the effect of intramuscular rAAV2-ApoA-I_{Milano} gene transfer on vein graft plaque size in accordance with an embodiment of the invention.

25 **FIGURE 7** shows the effect of intramuscular rAAV2-ApoA-I_{Milano} gene transfer on macrophage (MOMA) immunoreactivity in vein graft in accordance with an embodiment of the invention. **FIGURE 7A** depicts photographs of MOMA stained samples treated with PBS, control vector and rAAV2-ApoA-I_{Milano}. **FIGURE 7B** shows the relative percentage of MOMA immunoreactivity in the photographs in Figure 7A.

30 **FIGURE 8** shows the effect of intramuscular rAAV2-ApoA-I_{Milano} gene transfer on lipid content in vein graft in accordance with an embodiment of the invention. **FIGURE 8A** depicts photographs of stained samples showing lipid accumulation, for mice treated with PBS, control vector and rAAV2-ApoA-I_{Milano}. **FIGURE 8B** shows the relative percentage of lipid content in the photographs in Figure 8A.

FIGURE 9 shows the effect of intramuscular rAAV2-ApoA-I_{Milano} gene transfer on plaque size in aortic sinus in accordance with an embodiment of the invention.

FIGURE 10 shows the effect of intramuscular rAAV2-ApoA-I_{Milano} gene transfer on macrophage immunoreactivity in aortic sinus in accordance with an embodiment of the invention. FIGURE 10A depicts photographs of stained samples for PBS, control vector and rAAV2-ApoA-I_{Milano} treated mice. FIGURE 10B shows the relative percentage of macrophage immunoreactivity in the photographs in Figure 10A.

FIGURE 11 shows the effect of intramuscular rAAV2-ApoA-I_{Milano} gene transfer on lipid content in aortic sinus in accordance with an embodiment of the invention.

FIGURE 11A depicts photographs of stained samples showing lipid accumulation, for PBS, control vector and rAAV2-ApoA-I_{Milano} treated mice. FIGURE 11B shows the relative percentage of lipid content in the photographs in Figure 11A.

FIGURE 12 depicts photographs of aortic arch lesions in mice fed on a high fat diet in accordance with an embodiment of the invention. FIGURE 12A depicts a control aortic arch and FIGURE 12B depicts the aortic arch for a mouse receiving a bone marrow transplant transduced with rAAV2-ApoA-I_{Milano}. FIGURE 12C depicts a control aortic arch and the aortic arch for a mouse receiving intramuscular injection with rAAV2-ApoA-I_{Milano}.

FIGURE 13 shows aorta and large vessels extending from the aortic arch to femoral bifurcation isolated and stained with oil red O for the extent of atherosclerotic plaques after 20-24 weeks on a high fat diet in accordance with an embodiment of the invention. Ten million ApoE-/- bone marrow cells were transduced overnight (37 °C, IL-3 10 ng/ml, IL-6 10 ng/ml and SCF 1 ng/ml) with rAAV-ApoA-I_{Milano} at a multiplicity of infection (MOI) of 5000, washed (3X) and transplanted via the tail vein into 6-8 week old, lethally irradiated male Apo E-/- mice (1100 cGy, split dose). A high fat diet was initiated three weeks after the procedures for all treatment groups. FIGURE 13A shows the results for ApoE-/- mice transplanted with wild type marrow. This is a positive control for the experiment. FIGURE 13B shows results for ApoE-/- mice transplanted with rAAV-2-Apo A1 milano transduced bone marrow cells. Note mthe absence of Oil-red stained plaques. FIGURE 13C shows the results for ApoE-/- mice under high fat diet with no transplant. Lots of atherosclerotic plaques are visible. FIGURE 13D shows the results for ApoE-/- mice under high fat diet with untransduced bone marrow transplant.

FIGURE 14 shows the aorta and large vessels extending from the aortic arch to

femoral bifurcation isolated and stained with oil red O for the extent of atherosclerotic plaques after 20-24 weeks on a high fat diet in accordance with an embodiment of the invention. For the intramuscular injections, 6-8 week old ApoE-/- mice were injected with $1-5 \times 10^{12}$ vector genomes/kg (2 X 50 μ L in Gastrocnemeus muscle). A high fat diet 5 was initiated two weeks after injection. FIGURE 14A shows the results for mice with no injection. FIGURE 14B shows results for mice with control irrelevant rAAV-2 vector. FIGURE 14C shows the results after IM injection with rAAV2-ApoA-I_{Milano}. FIGURE 14D shows the results after IM injection with rAAV5-ApoA-I_{Milano}.

10 FIGURE 15 shows the anti-atherogenic effects of a single rAAV-ApoA-I_{Milano} intramuscular injection in accordance with an embodiment of the invention. The graph shows the percentage of aortic surface with plaque for control, untransfected rAAV vector and rAAV2-ApoA-I_{Milano} treated mice.

15 FIGURE 16 shows the inhibition of plaque formation following a single intramuscular injection of rAAV-ApoA-I_{Milano} in accordance with an embodiment of the invention. The graph shows the percentage of aortic surface with plaque in control, untransfected rAAV vector and rAAV1-, rAAV2- and rAAV5-ApoA-I_{Milano} treated mice.

20 FIGURE 17 shows the a reduction in lipid and macrophage content in aortic plaques of ApoE-deficient mice following a single intramuscular injection of rAAV-ApoA-I_{Milano} in accordance with an embodiment of the invention. The graphs show the percentage of lipid in aortic sinus and percentage of macrophage immunoreactivity for control and rAAV2-ApoA-I_{Milano} treated mice.

25 FIGURE 18 shows the a reduction in atherosclerosis in ApoE null mice following transplantation of bone marrow transduced with rAAV-ApoA-I_{Milano} in accordance with an embodiment of the invention. The graph shows the percentage of aortic plaque for control, untransduced bone marrow transplant, untransfected rAAV vector, rAAV1-, rAAV2- and rAAV5-ApoA-I_{Milano}, and ApoE-/- bone marrow treated mice.

30 FIGURE 19 shows the a reduction in lipid and macrophage content of aortic plaques of ApoE-deficient mice following transplantation of bone marrow transduced with rAAV-ApoA-I_{Milano} in accordance with an embodiment of the invention. The graphs show the percentage of lipid in aortic sinus and percentage of macrophage immunoreactivity for control and rAAV2-ApoA-I_{Milano} treated mice.

FIGURE 20 shows the comparative anti-atherogenic effects for a transplantation of bone-marrow transduced with retrovirus carrying ApoA-I (wild-type) and ApoA-I_{Milano} gene in accordance with an embodiment of the invention. The graph shows the

percentage of aortic atheroma for control, ApoA-I wild-type and ApoA-I_{Milano} treated mice.

5 **FIGURE 21** shows the wild-type rAAV vector construction encoding the human ApoA-I_{Milano} gene inserted into the genome in accordance with an embodiment of the present invention. This construct will be inserted into the genome after gene delivery – or it may survive in the cells without genomic insertion, both of which are possible for AAV.

10 **FIGURE 22** shows the vector maps of rAAV vector serotypes 2 and 5 encoding the human ApoA-I_{Milano} gene inserted into the genome in accordance with an embodiment of the present invention. These constructs will be inserted into the genome after gene delivery – or they may survive in the cells without genomic insertion, both of which are possible for AAV.

DETAILED DESCRIPTION OF THE INVENTION

15 All publications cited herein are incorporated by reference in their entirety as though fully set forth. Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton *et al.*, Dictionary of Microbiology and Molecular Biology 2nd ed., J. Wiley & Sons (New York, NY 1994); March, Advanced Organic Chemistry Reactions, Mechanisms and Structure 4th ed., J. Wiley & Sons 20 (New York, NY 1992); and Sambrook and Russel, Molecular Cloning: A Laboratory Manual 3rd ed., Cold Spring Harbor Laboratory Press (Cold Spring Harbor, NY 2001), provide one skilled in the art with a general guide to many of the terms used in the present application.

25 One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. Indeed, the present invention is in no way limited to the methods and materials described. For purposes of the present invention, the following terms are defined below.

30 “Conditions” and “disease conditions,” as used herein may include, but are in no way limited to any form of coronary heart disease and/or vascular disease and/or their pathology; in particular, atherosclerosis.

“Pathology” of coronary heart disease and/or vascular disease includes all phenomena that compromise the well-being of the patient. This includes, without

limitation, all forms of arterio-sclerosis, including atherosclerosis, atherogenesis, vascular inflammation, release of cytokines or other secretory products at abnormal levels, suppression or aggravation of inflammatory or immunological response, etc.

“Atherosclerosis” describes the progressive narrowing and hardening of the 5 arteries over time. This is known to occur to some degree with aging, but other risk factors that accelerate this process have been identified. These factors include: high cholesterol, high blood pressure, smoking, diabetes and family history for atherosclerotic disease. “Atherogenesis,” commonly associated with formation of atheroma is important in the pathogenesis of “arteriosclerosis” and atherosclerosis.

10 “Gene transfer” or “gene delivery” refers to methods or systems for reliably inserting foreign DNA into host cells. Such methods can result in transient expression of non-integrated transferred DNA, extrachromosomal replication and expression of transferred replicons (e.g., episomes), or integration of transferred genetic material into the genomic DNA of host cells. Gene transfer provides a unique approach for the 15 treatment of acquired and inherited diseases. A number of systems have been developed for gene transfer into mammalian cells. See, e.g., U.S. Patent No. 5,399,346.

“Vector” refers to any genetic element, such as a plasmid, phage, transposon, 20 cosmid, chromosome, virus, virion, etc., which is capable of replication when associated with the proper control elements and which can transfer gene sequences between cells. Thus, the term includes cloning and expression vehicles, as well as viral vectors.

“AAV vector” refers to any vector derived from any adeno-associated virus 25 serotype, including, without limitation, AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-7 and AAV-8, and the like. AAV vectors can have one or more of the AAV wild-type genes deleted in whole or in part, preferably the *Rep* and/or *Cap* genes, but retain functional flanking ITR sequences. Functional ITR sequences are generally necessary for the rescue, replication, packaging and potential chromosomal integration of the AAV genome. Thus, an AAV vector is defined herein to include at least those sequences 30 required in *cis* for replication and packaging (e.g., functional ITRs) of the virus. The ITRs need not be the wild-type nucleotide sequences, and may be altered (e.g., by the insertion, deletion or substitution of nucleotides) so long as the sequences provide for functional rescue, replication and packaging.

“Recombinant virus” refers to a virus that has been genetically altered (e.g., by

the addition or insertion of a heterologous nucleic acid construct into the particle).

"AAV virion" refers to a complete virus particle, such as a wild-type ("wt") AAV virus particle (*i.e.*, including a linear, single-stranded AAV nucleic acid genome associated with an AAV capsid protein coat). In this regard, single-stranded AAV nucleic acid molecules of either complementary sense (*i.e.*, "sense" or "antisense" strands) can be packaged into any one AAV virion; both strands are equally infectious. In addition, the AAV capsid protein coat can be from any of the various AAV serotypes depending on the target of the AAV virion.

A "recombinant AAV virion" or "rAAV virion" is defined herein as an infectious, replication-defective virus composed of an AAV protein shell, encapsidating a heterologous DNA molecule of interest (*e.g.*, genes encoding ApoA-I, ApoA-I_{Milano}) which is flanked on both sides by AAV ITRs. A rAAV virion may be produced in a suitable host cell which has had an AAV vector, AAV *Rep* and *Cap* functions and helper virus functions introduced therein. In this manner, the host cell is rendered capable of producing AAV replication and capsid proteins that are required for replicating and packaging the AAV vector (*i.e.*, containing a recombinant nucleotide sequence of interest) into recombinant virion particles for subsequent gene delivery. The complete transgene may consist of a promoter, the coding sequences, usually a cDNA and a polyadenylation signal. A transgene may also include regulatory sequences and intron regions. Promoters that would regulate transgene expression may include constitutive, inducible and tissue-specific promoters.

The term "transfection" is used herein to refer to the uptake of foreign DNA by a cell. A cell has been "transfected" when exogenous DNA has been introduced inside the cell membrane. A number of transfection techniques are generally known in the art.

25 See, *e.g.*, Graham *et al.* (1973) *Virology*, 52:456, Sambrook *et al.* (1989) *Molecular Cloning, a laboratory manual*, Cold Spring Harbor Laboratories, New York, Davis *et al.* (1986) *Basic Methods in Molecular Biology*, Elsevier, and Chu *et al.* (1981) *Gene* 13:197. Such techniques can be used to introduce one or more exogenous DNA moieties, such as a plasmid vector and other nucleic acid molecules, into suitable host 30 cells. The term refers to both stable and transient uptake of the genetic material.

The term "transduction" denotes the delivery of a DNA molecule to a recipient cell either *in vivo* or *in vitro*, via any method of gene delivery, including replication-defective viral vectors, such as via a rAAV.

The term "heterologous," as it relates to nucleic acid sequences such as gene

sequences and control sequences, denotes sequences that are not normally joined together and/or are not normally associated with a particular virus. Allelic variation or naturally occurring mutational events do not give rise to heterologous DNA, as used herein.

5 "DNA" is meant to refer to a polymeric form of deoxyribonucleotides (i.e., adenine, guanine, thymine and cytosine) in double-stranded or single-stranded form, either relaxed or supercoiled. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes single- and double-stranded DNA found, *inter alia*, in linear DNA
10 molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes. In discussing the structure of particular DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the non-transcribed strand of DNA (i.e., the strand having the sequence homologous to the mRNA). The term captures molecules that include the four bases
15 adenine, guanine, thymine and cytosine, as well as molecules that include base analogues which are known in the art.

A "gene" or "coding sequence" or a sequence which "encodes" a particular protein is a nucleic acid molecule that is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide *in vitro* or *in vivo* when placed under the
20 control of appropriate regulatory sequences; although one of skill in the art will readily appreciate that various polynucleotides do not operate in this fashion (e.g., antisense RNA, siRNA, ribozymes, wherein the RNA transcript is the product). With respect to protein products (i.e., not RNA products), the boundaries of the coding sequence are determined by a start codon at the 5' (i.e., amino) terminus and a translation stop codon
25 at the 3' (i.e., carboxy) terminus. A gene can include, but is not limited to, cDNA from prokaryotic or eukaryotic mRNA, genomic DNA sequences from prokaryotic or eukaryotic DNA, and even synthetic DNA sequences. A transcription termination sequence will usually be located 3' to the gene sequence. Moreover, a "gene" (i) starts with a promoter region containing multiple regulatory elements, possibly including
30 enhancers, for directing transcription of the coding region sequences; (ii) includes coding sequences, which start at the transcriptional start site that is located upstream of the translational start site and ends at the transcriptional stop site, which may be quite a bit downstream of the stop codon (a polyadenylation signal is usually associated with the transcriptional stop site and is located upstream of the transcriptional stop); and (iii)

may contain introns and other regulatory sequences to modulate expression and improve stability of the RNA transcript.

The term "control elements" refers collectively to promoter regions, polyadenylation signals, transcription termination sequences, upstream regulatory domains, origins of replication, internal ribosome entry sites ("IRES"), enhancers, and the like, which collectively provide for the replication, transcription and translation of a coding sequence in a recipient cell. Not all of these control elements need always be present, so long as the selected coding sequence is capable of being replicated, transcribed and translated in an appropriate host cell.

The term "promoter region" is used herein in its ordinary sense to refer to a nucleotide region including a DNA regulatory sequence, wherein the regulatory sequence is derived from a gene which is capable of binding RNA polymerase and initiating transcription of a downstream (3'-direction) coding sequence.

"Operably linked" refers to an arrangement of elements wherein the components so described are configured so as to perform their usual function. Thus, control elements operably linked to a coding sequence are capable of effecting the expression of the coding sequence. The control elements need not be contiguous with the coding sequence, so long as they function to direct the expression thereof. Thus, for example, intervening untranslated yet transcribed sequences can be present between a promoter sequence and the coding sequence and the promoter sequence can still be considered "operably linked" to the coding sequence.

For the purpose of describing the relative position of nucleotide sequences in a particular nucleic acid molecule throughout the instant application, such as when a particular nucleotide sequence is described as being situated "upstream," "downstream," "5'," or "3" relative to another sequence, it is to be understood that it is the position of the sequences in the non-transcribed strand of a DNA molecule that is being referred to as is conventional in the art.

"Stem Cells" is a term used to describe all cells that can give rise to cells of multiple tissue types. "Multipotent stem cells" as used herein refer to undifferentiated cells with the capacity for extensive proliferation that gives rise to more cells as well as progeny that can terminally differentiate into the cell types found in the tissue from which they were derived, such as blood stem cells that give rise only to red blood cells, white blood cells and platelets, or skin stem cells that give rise only to the various types

of skin cells. Other examples, include, for example, bone marrow cells, hematopoietic stem cells, mesenchymal cells, etc.

“Homology” and “homologous” as used herein refer to the percent of identity between two polynucleotide or two polypeptide moieties. The correspondence between 5 the sequence from one moiety to another can be determined by techniques known in the art. For example, homology can be determined by a direct comparison of the sequence information between two polypeptide molecules by aligning the sequence information and using readily available computer programs. Alternatively, homology can be determined by hybridization of polynucleotides under conditions which form 10 stable duplexes between homologous regions, followed by digestion with single-stranded-specific nuclease(s), and size determination of the digested fragments. Two DNA or two polypeptide sequences are “substantially homologous” to each other when at least about 80%, preferably at least about 90%, and most preferably at least about 95% of the nucleotides or amino acids, respectively, match over a defined length of the 15 molecules, as determined using the methods above.

“Isolated” as used herein when referring to a nucleotide sequence, vector, etc., refers to the fact that the indicated molecule is present in the substantial absence of other biological macromolecules of the same type. Thus, an “isolated nucleic acid molecule which encodes a particular polypeptide” refers to a nucleic acid molecule that 20 is substantially free of other nucleic acid molecules that do not encode the subject polypeptide. Likewise, an “isolated vector” refers to a vector that is substantially free of other vectors that differ from the subject vector. However, the subject molecule or vector may include some additional bases or moieties that do not deleteriously affect the basic characteristics of the composition.

25 “Purified” as used herein when referring to a vector, refers to a quantity of the indicated vector that is present in the substantial absence of other biological macromolecules. Thus, a “purified vector” refers to a composition that includes at least 80% subject vector, preferably at least 90% subject vector, most preferably at least 95% subject vector with respect to other components of the composition

30 “Mammal” as used herein refers to any member of the class *Mammalia*, including, without limitation, humans and nonhuman primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs, and the like. The term does not denote a

particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be included within the scope of this term.

The present invention is based on a gene therapeutic approach to increase the expression of ApoA-I_{Milano} in a mammal for the prevention and treatment of 5 atherosclerosis. The gene therapy is nonpathogenic and results in persistent levels of circulating ApoA-I_{Milano}.

ApoA-I_{Milano} has demonstrated marked efficacy in the reduction of atherosclerosis in animal models. Recent human trials of recombinant ApoA-I_{Milano} infusions have similarly shown marked reduction in atheroma volumes. Here, the efficacy of rAAV 10 vectors encoding ApoA-I_{Milano} for gene therapy of atherosclerosis *in vivo* following either intramuscular injection or transplantation of rAAV-transduced bone marrow cells was tested.

The vectors of the present invention are based on the vector described in U.S. Patent No.: 5,474,935, with the transgene being ApoA-I_{Milano} for the treatment of 15 atherosclerosis. Preparation of rAAV vectors was completed as previously described (Chatterjee, S. & K.K. Wong, Adeno-associated virus vectors for the delivery of ribozymes. *In* "Intracellular Ribozyme Applications: Principles and Protocols," JJ Rossi and L. Couture (Eds.), Horizon Scientific Press, pp. 189-215 (2000); Chatterjee, S. *et al.*, "Transduction of primitive human marrow and cord blood-derived hematopoietic 20 progenitor cells with adeno-associated virus vector," *Blood*, Vol. 93, pp. 1882-1894 (1999)). Transgene delivery systems have frequently included the use of the CMV immediate early promoter (Fitzsimons, H.L. *et al.*, "Promoters and regulatory elements that improve adeno-associated virus transgene expression in the brain," *Methods*, Vol. 28, pp. 227-36 (2002); Phillips, M.I., "Gene therapy for hypertension: sense and 25 antisense strategies," *Expert Opin Biol Ther*, Vol. 1, pp. 655-62 (2001); Smith, L.C. *et al.*, "Advances in plasmid gene delivery and expression in skeletal muscle," *Curr Opin Mol Ther*, Vol. 2, pp. 150-4 (2000); Keating, A. *et al.*, "Effect of different promoters on expression of genes introduced into hematopoietic and marrow stromal cells by electroporation," *Exp Hematol*, Vol. 18, pp. 99-102 (1990); Muller, S.R. *et al.*, "Efficient 30 transfection and expression of heterologous genes in PC12 cells," *DNA Cell Biol*, Vol. 9, pp. 221-9 (1990)) since it is one of the most active promoters among viral and eukaryotic species without a specific host cell type requirement. However, any number of promoters may be used in constructing the rAAV vectors of the present invention as

will be recognized by one of skill in the art. For example, the rAAV-5 vector used in the present invention incorporates a CBA promoter.

The construction of the vectors of the present invention is completed by widely recognized means for manufacturing AAV virions, which entails co-transfection of a host cell with two different, yet complementing plasmids. One of these contains the therapeutic or reporter transgene sandwiched between the two cis acting AAV ITRs. The AAV components that are needed for rescue and subsequent packaging of progeny recombinant genomes are provided in trans by a second plasmid encoding the viral open reading frames for rep and cap proteins. However, any number of other techniques for construction of the vectors of the present invention may be used as will be recognized by one of skill in the art. See, e.g. Gao, G. (2002) *Proc Natl Acad Sci USA* 99:11854-11859; Hauck, B. (2003) *Journal of Virology* 77(4):2768-2774; Gao, G. (2004) *Journal of Virology* 78(12):6381-6388. Still other methods may be used for construction of the vectors of the present invention, for example, U.S. Pat. No. 5,658,776 refers to packaging systems and processes for packaging AAV vectors that replace the AAV P5 promoter with a heterologous promoter. Alternatively, U.S. Pat. No. 5,622,856 refers to constructs and methods for AAV vector production, which provide constructs formed by moving the homologous P5 promoter to a position 3' to the rep genes, and optionally flanking the rep-cap and repositioned P5 promoter with FRT sequences.

Furthermore, in various embodiments of the invention, the ITRs and portions of the genome of the first plasmid and the rep and cap proteins of the second plasmid can be derived from any serotype of AAV vector. In this way, the rAAV virions of the present invention can be specifically tailored to target a subject tissue with greater specificity. It is well known in the art that AAV serotype has a significant impact on tissue-specific gene expression (Hauck, B. *et al.*, "Generation and characterization of chimeric recombinant AAV vectors," *Mol Ther*, Vol. 7, pp. 419-25 (2003); Chao, H. *et al.*, "Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors," *Mol Ther*, Vol. 2, pp. 619-23 (2000); Xiao, W. *et al.*, "Gene therapy vectors based on adeno-associated virus type 1," *J Virol*, Vol. 73, pp. 3994-4003 (1999); Rabinowitz, J.E. *et al.*, "Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity," *J Virol*, Vol. 76, pp. 791-801 (2002); Alisky, J.M. *et al.*, "Transduction of murine cerebellar neurons with recombinant FIV and AAV5 vectors,"

Neuroreport, Vol. 11, pp. 2669–73 (2000); Chiorini, J.A. *et al.*, “Cloning and characterization of adeno-associated virus type 5,” *J Virol*, Vol. 73, pp. 1309–19 (1999); Davidson, B.L. *et al.*, “Recombinant adeno-associated virus type 2,4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system,” *Proc Natl Acad Sci USA*, Vol. 97, pp. 3428–32 (2000); Rutledge, E.A. *et al.*, “Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2,” *J Virol*, Vol. 72, pp. 309–19 (1998)). For example, the DNA element of the first plasmid may be derived from one AAV serotype, the rep proteins may be derived from another AAV serotype, and the cap proteins may be derived from still another AAV serotype. In particular, the AAV vector genome can be pseudotyped by packaging with capsids from different AAV serotypes, which has been effective in directing rAAV gene therapies to specific tissues (Weitzman, M. *et al.*, “Breaking the barriers to global gene delivery,” *Nature Biotechnology*, Vol. 23, Issue 3, pp. 305-306 (2005); Wang, Z. *et al.*, “Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart,” *Nature Biotechnology*, Vol. 23, Issue 3, pp. 321-328 (2005); Wang, L. *et al.*, “Sustained correction of disease in naïve and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy,” *Gene Therapy*, Vol. 105, Issue 8, pp. 3079-3086 (2005)). In various embodiments of the present invention, capsids derived from AAV serotypes 1, 8, 9 and 10 may be particularly effective in intramuscular injections. Further, capsids derived from AAV serotypes 1,7 and 8 may be particularly effective for hematopoietic stem cell transduction. Still further, capsids derived from AAV serotype 8 may be particularly effective targeting the liver.

In the animal model upon which the present invention is based, ApoE-/- mice were injected with approximately 10¹² vector genomes/kg at 6-8 weeks of age and placed on a high fat diet two weeks later. No major differences in body weight were observed between the treatment groups. Approximately 20-24 weeks after injection, the mice were harvested, aortas were cleaned, fixed, mounted, stained with oil red O and atherosclerotic plaque areas quantified. Control untreated mice or mice treated with an irrelevant rAAV vector showed marked atherosclerotic lesion formation. In contrast, the rAAV-2-ApoA-I_{Milano} and rAAV-5-ApoA-I_{Milano} injected groups showed significant reductions in plaque formation, 58% and 50% respectively, despite a lack of major differences in total plasma cholesterol levels. Since marrow-derived monocytes and macrophages play a pivotal role in atherogenesis, it was hypothesized that transplantation of rAAV ApoA-I_{Milano}-transduced marrow cells would also result in a

decline in plaque formation, possibly due to the localization of transduced macrophages within atherosclerotic lesions. Lethally irradiated Apo E-/- mice were transplanted with rAAV transduced cells, and high fat diet was initiated three weeks later. Twenty two to 24 weeks after transplantation, the mice were euthanized, and aortas were analyzed for 5 atherosclerotic plaques. Untransplanted mice, and mice transplanted with untransduced and control rAAV transduced marrow served as negative controls. Wild type B6 to Apo E-/- transplants served as positive controls for plaque reduction. Results revealed a 41% and 47% reduction in atheroma formation following 10 transplantation with cells transduced with rAAV-2 and rAAV-5 vectors encoding ApoA-I_{Milano}, respectively. These results suggest that either intramuscular injection of rAAV- ApoA-I_{Milano} or transplantation of rAAV-ApoA-I_{Milano} transduced marrow cells results in significant long-term inhibition of atherogenesis following a single treatment with an rAAV-ApoA-I_{Milano} vector.

The methods of the present invention relate to the treatment, prevention, 15 inhibition, stabilization and/or induction of regression of atherosclerosis, as well as the treatment, prevention, inhibition and/or stabilization of any disease or physiological condition in which atherosclerosis (or atherogenesis) plays a role. Furthermore, the methods of the present invention may be particularly useful in treating atherosclerosis when caused by invasive techniques, such as percutaneous transluminal coronary 20 angioplasty ("PTCA"); insertion of a bypass graft or stent insertion; treatment of restenosis following stent placement; or as a result of bypass graft insertion. Each of the aforementioned applications is contemplated as being within the scope of the present invention. Still further, other diseases and physiological conditions that may benefit from the methods of the present invention will be readily apparent to those of 25 skill in the art, and are also contemplated as being within the ambit of the present invention.

The invention is based on a gene therapeutic approach to the treatment of coronary heart disease and/or vascular disease. In one embodiment of the invention, rAAV virions including heterologous DNA corresponding to an ApoA-I or ApoA-I_{Milano} 30 coding sequence are generated by any conventional technique known in the art. By way of example, the recombinant AAV virions of the present invention, including the ApoA-I or ApoA-I_{Milano} DNA of interest, can be produced by a standard methodology that generally involves the steps of: (1) introducing an AAV vector plasmid into a host cell; (2) introducing an AAV helper construct into the host cell, where the helper

construct includes AAV coding regions capable of being expressed in the host cell to complement AAV helper functions missing from the AAV vector; (3) introducing one or more helper viruses and/or accessory function vectors into the host cell, wherein the helper virus and/or accessory function vectors provide accessory functions capable of supporting efficient rAAV virion production in the host cell; and (4) culturing the host cell to produce rAAV virions. The AAV vector, AAV helper construct and the helper virus or accessory function vector(s) can be introduced into the host cell either simultaneously or serially, using standard transfection techniques. Any number of other approaches may also be used, as will be readily recognized by one of skill in the art.

AAV vectors are constructed using known techniques to at least provide, as operatively linked components in the direction of transcription, (a) control elements including a transcriptional initiation region, (b) the ApoA-I or ApoA-I_{Milano} DNA of interest and (c) a transcriptional termination region. Moreover, any coding sequence sufficiently homologous to the ApoA-I or ApoA-I_{Milano} coding sequence so as to exhibit functional properties substantially similar to the ApoA-I or ApoA-I_{Milano} coding sequence may be used in connection with alternate embodiments of the present invention. The control elements are selected to be functional in the targeted cell(s). The resulting construct, which contains the operatively linked components, may be bounded (5' and 3') with functional AAV ITR sequences. The nucleotide sequences of AAV ITR regions are known. See, e.g., Kotin, R.M. (1994) *Human Gene Therapy* 5:793-801; Berns, K.I., "Parvoviridae and their Replication" in *Fundamental Virology*, 2nd Edition, (B.N. Fields and D.M. Knipe, eds.) for the AAV-2 sequence. AAV ITRs used in the vectors of the invention need not have a wild-type nucleotide sequence, and may be altered (e.g., by the insertion, deletion or substitution of nucleotides). Additionally, AAV ITRs may be derived from any of several AAV serotypes, including, without limitation, AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-7, AAV-8, AAV-9, AAV-10 and the like. See, e.g. Gao *et al.*, J Virol. 2004 Jun;78(12):6381-8; Weitzman, M. *et al.* (2005); Wang, Z. *et al.* (2005); and Wang, L. *et al.* (2005). Furthermore, 5' and 3' ITRs that flank a selected nucleotide sequence in an AAV expression vector need not necessarily be identical or derived from the same AAV serotype or isolate, so long as they function as intended (i.e., to allow for excision and replication of the bounded ApoA-I or ApoA-I_{Milano} nucleotide sequence of interest).

The rAAV genome encoding the ApoA-I or ApoA-I_{Milano} transgenes within AAV ITRs may be packaged in virion capsids derived from any AAV serotype including AAV-

1, AAV-2, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10 and the like. See, e.g. Gao *et al.* (2004); Weitzman, M. *et al.* (2005); Wang, Z. *et al.* (2005); and Wang, L. *et al.* (2005).

The virions described above are useful for preventing and treating coronary heart disease and/or vascular disease and thus are useful for the manufacture of pharmaceutical compositions which contain an effective amount of rAAV-ApoA-I_{Milano} vectors in admixture with inorganic or organic, solid or liquid, pharmaceutically acceptable carriers. Thus, another aspect of this invention is a composition for preventing and treating coronary heart disease and/or vascular disease described herein in combination with a pharmaceutically acceptable excipient.

The pharmaceutical compositions according to the invention are those which are suitable for oral, transdermal, topical, or parenteral, such as intramuscular or intravenous, administration to humans, and which contain the pharmacologically active rAAV transfected vectors together with a pharmaceutically acceptable carrier. The dosage depends on various factors such as the age, weight, severity of vascular condition, and other factors a doctor might identify.

In certain embodiments, the therapeutic compositions are administered via suppository, or in tablet or capsule formulations for oral delivery. Oral formulations usually include such normally employed additives such as binders, fillers, carriers, preservatives, stabilizing agents, emulsifiers, buffers and excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, enterics, sustained release formulations, powders, and the like. Oral formulations for gene therapy are known in the art. See, e.g. Chen, J. *et al.* (2004) World J. Gastroenterol 10(1):112-116. Further, other oral formulations are contemplated for use in the present invention as will be recognized by one of skill in the art.

Additional formulations which are suitable for other modes of administration, such as transdermal and topical administration, include salves, tinctures, creams, lotions, transdermal patches, transplanted skin, genetically engineered skin, stent coatings and suppositories. For salves and creams, traditional binders, carriers and excipients may include, for example, polyalkylene glycols or triglycerides. In certain embodiments, a transdermal patch may be used for delivering therapeutics. See, e.g. U.S. Pat. No. 4,638,043. Transdermal and topical formulations for gene therapy are

know in the art. See, e.g. Jensen, TG (2004) Expert Opin Biol Ther. 4(5):677-82.

Further, other transdermal and topical formulations are contemplated for use in the present invention as will be recognized by one of skill in the art.

Particularly suitable dosage forms for parenteral administration are sterile

5 aqueous solutions of the pharmacologically active rAAV transfected vectors in water-soluble form, for example, a water-soluble salt, or sterile aqueous injection suspensions which contain substances increasing the viscosity, for example, sodium, carboxymethyl cellulose, sorbitol and/or dextran, and optionally stabilizers. In addition, the pharmacologically active rAAV transfected vectors, with or without adjuvants, can also

10 be in lyophilized form and brought into solution prior to parenteral administration by the addition of suitable solvents.

Generally, an injectable composition of the invention may be a solution that is ready for injection, or a dry soluble composition that is ready to be combined with a solvent just prior to use, or a liquid concentrate ready for dilution prior to administration.

15 In preparing a composition for injection strict attention must be paid to tonicity adjustment to avoid irritation.

The vehicle normally has no therapeutic activity and is nontoxic, but presents the pharmacologically active rAAV transfected vectors to the body tissues or circulation in a form appropriate for absorption. Absorption normally will occur most rapidly and

20 completely when the pharmacologically active rAAV transfected vectors is presented as an aqueous solution. However, modification of the vehicle with water-miscible liquids or substitution with water-immiscible liquids can affect the rate of absorption. In preparing the compositions which are suitable for subcutaneous injection, one can use aqueous vehicles, water-miscible vehicles, and nonaqueous vehicles. Certain aqueous vehicles

25 are recognized officially because of their valid use in parenterals generally.

Water-miscible vehicles are also useful in the formulation of the parenteral composition of this invention. These solvents are used primarily to affect the solubility of the pharmacologically active rAAV transfected vectors. These solvents may include, for example, ethyl alcohol, polyethylene glycol and propylene glycol.

30 Additional substances may be included in the injectable compositions of this invention to improve or safeguard the quality of the composition. Thus, an added substance may affect solubility, provide for patient comfort, enhance the chemical stability, or protect preparation against the growth of microorganisms. Thus, the composition may include an appropriate solubilizer, substances to make a solution

isotonic, substances to act as antioxidants, and substances that act as a preservative to prevent the growth of microorganisms. These substances will be present in an amount that is appropriate for their function, but will not adversely affect the action of the composition as a treatment for disease conditions as contemplated herein.

5 Generally, the sterile, parenterally injectable composition of this invention and other therapeutic formulations suitable for delivery to a mammal in accordance with various embodiments of the present invention can be readily prepared by routine experimentation by the skilled artisan. Guidance as to suitable pharmaceutical formulations are provided by Remington: The Science and Practice of Pharmacy 19th

10 Ed.

 In accordance with an embodiment of the invention, the rAAV virions encoding ApoA-I or ApoA-I_{Milano} are delivered to a mammal in a sufficient quantity and by a sufficient delivery route so as to effect gene transfer. As described in the ensuing Examples, this provides an effective treatment for atherosclerosis in mammals. In 15 various embodiments, a sufficient and therapeutic quantity may be from about 1 x 10¹⁰ vector genome/kg to about 1 x 10¹⁴ vector genome/kg of rAAV-ApoA-I or rAAV-ApoA-I_{Milano} vectors *in vivo*. In one embodiment of the present invention, the rAAV-ApoA-I or rAAV-ApoA-I_{Milano} vector may be delivered to a subject by first transducing multipotent stem cells (e.g., bone marrow cells, blood stem cells, stromal cells, mesenchymal stem 20 cells etc.) with a quantity of the rAAV-ApoA-I_{Milano} vector, and then transplanting these cells into a mammal. In an alternate embodiment, the rAAV-ApoA-I_{Milano} vector may be introduced into a mammal by direct intramuscular or intravenous injection, or directly into the artery at the site of PTCA or stent placement by any conventional methodology, as will be readily appreciated by one of skill in the art. This results in secretion of 25 ApoA-I_{Milano} either directly into the circulation or locally in atherosclerotic plaque areas. Further, the rAAV virions of the present invention can be delivered as a single administration or as a treatment regimen, e.g., daily, weekly, or at any other suitable time interval, as will be readily recognized by one of skill in the art. In another embodiment of the present invention, one serotype of rAAV virion can be delivered as a 30 single administration followed by delivery of a different serotype of rAAV virion.

 The present invention is also directed to a kit for the treatment of atherosclerosis and related disease conditions in a subject. The kit is an assemblage of materials or components, including at least one means of effecting gene transfer of ApoA-I or ApoA-I_{Milano} in a subject in accordance with various embodiments of the present

invention. The exact nature of the components configured in the inventive kit depends on its intended purpose and on the particular methodology that is employed. For example, some embodiments of the kit are configured for the purpose of treating atherosclerosis and/or related disease conditions in a mammalian subject. Other 5 embodiments are configured for the purpose of preventing the onset of atherosclerosis that is the result of another therapy, e.g., angioplasty or stent placement. In one embodiment, the kit is configured particularly for the purpose of treating human subjects.

Instructions for use may be included with the kit. "Instructions for use" typically 10 include a tangible expression describing the preparation of virions and/or at least one method parameter, such as the relative amounts of rAAV-ApoA-I and/or rAAV-ApoA-I_{Milano} vector genome, dosage requirements and administration instructions, and the like, typically for an intended purpose. Optionally, the kit also contains other useful 15 components, such as, diluents, buffers, pharmaceutically acceptable carriers, specimen containers, syringes, stents, catheters, and pipetting or measuring tools.

The materials or components assembled in the kit can be provided to the practitioner stored in any convenient and suitable ways that preserve their operability and utility. For example the components can be in dissolved, dehydrated, or lyophilized form; they can be provided at room, refrigerated, or frozen temperatures. 20 The components are typically contained in suitable packaging material(s). As employed herein, the phrase "packaging material" refers to one or more physical structures used to house the contents of the kit. The packaging material is constructed by well known methods, preferably to provide a sterile, contaminant-free environment. The packaging materials employed in the kit are those customarily utilized in the field. 25 As used herein, the term "package" refers to a suitable solid matrix or material such as glass, plastic, paper, foil, and the like, capable of holding the individual kit components. Thus, for example, a package can be a glass vial used to contain suitable quantities of a composition containing a volume of rAAV-ApoA-I and/or rAAV-ApoA-I_{Milano} vector. The packaging material generally has an external label which indicates the contents 30 and/or purpose of the kit and/or its components.

The tools, kits, and methods of the present invention may be implemented in connection with a gene therapeutic approach for treating atherosclerosis and related disease conditions. The various embodiments of the present invention may therefore provide a means for prevention of the aforementioned disease conditions. The

embodiments of the invention are also suitable for use in connection with monitoring the success of ongoing or completed therapeutic intervention. For instance, a subject's serum may be tested prior to treatment to screen for circulating levels of ApoA-I and/or ApoA-I_{Milano}; during the course of treatment (e.g., to enhance a physician's ability to 5 implement an effective treatment regimen); and/or following the completion of an intervention to determine a level of success (e.g., lifestyle changes, angioplasty and bypass surgery).

EXAMPLES

The following Examples demonstrate the success of gene therapy in treating 10 atherosclerosis using rAAV vectors encoding ApoA-I_{Milano}. The Examples further demonstrate the success of these vectors, *in vivo*, following either intramuscular injection or transplantation of rAAV-transduced hematopoietic progenitor cells. These Examples are included merely for purposes of illustration, as the present invention may be implemented in a number of ways not described in these Examples.

15

EXAMPLE 1

Construction of recombinant adeno-associated virus vectors

The construction of the rAAV vectors of the present invention was completed by co-transfected a host cell with two different plasmids. rAAV virions were prepared with the plasmids derived from various AAV serotypes. In each of the first plasmids, 20 ApoA-I_{Milano} was sandwiched between the two cis acting AAV ITRs. The AAV rep and cap proteins were provided in trans by a second plasmid encoding the viral open reading frames for rep and cap proteins of AAV. In one virion, rAAV2, the first plasmid genome was derived from AAV serotype 2 and the second plasmid was derived from AAV serotype 2 (Rep2Cap2). In a second virion, rAAV5, the first plasmid genome was 25 derived from AAV serotype 5 and the second plasmid was derived from AAV serotype 5 (Rep5Cap5). In a third virion, rAAV1, the first plasmid genome was derived from AAV serotype 2 and the second plasmid was derived from AAV serotypes 2 and 1 (Rep2Cap1). In a fourth virion, rAAV7, the first plasmid genome was derived from AAV serotype 2 and the second plasmid was derived from AAV serotypes 2 and 7 30 (Rep2Cap7). In a fifth virion, rAAV8, the first plasmid genome was derived from AAV serotype 2 and the second plasmid was derived from AAV serotypes 2 and 8 (Rep2Cap8). In a sixth virion, rAAV9, the first plasmid genome was derived from AAV

serotype 2 and the second plasmid was derived from AAV serotypes 2 and 9 (Rep2Cap9). Other virions may be readily implemented as part of the present invention, as will be recognized by one of skill in the art.

EXAMPLE 2

5

Animal procedures

Eight- to 12-week-old ApoA-I-deficient mice (obtained from Jackson Laboratory; Bar Harbor, ME) were used for viral transduction. Mice were restrained for intravenous injection of rAAV into the tail-vein and intramuscular injection into the hind leg. Blood samples were obtained by retro-orbital bleeding while animals were under anesthesia 10 with isoflurane. The use of experimental animals was in accordance with the guidelines of the CSHS Institutional Animal Care and Uses Committee.

EXAMPLE 3

rAAV Vectors Encoding ApoA-I_{Milano} Demonstrate Anti-atherogenic Properties in Animal Model

15 The anti-atherogenic properties of rAAV vectors encoding ApoA-I_{Milano} were tested in homozygous transgenic Apolipoprotein E ("ApoE") -/- mice. These mice develop large vessel atherosclerotic plaques when fed a high fat diet. Foam cells, which play a pivotal role in atherogenesis, arise from bone marrow-derived macrophages, and transplantation with wild type bone marrow cells has been shown to 20 prevent the onset of atherosclerosis in ApoE -/- mice. In this study the hypothesis that transplantation of transduced bone marrow cells would protect against the development of atherosclerosis was tested. The efficacy of transplantation with ApoA-I_{Milano} transduced bone marrow cells in reducing the extent of atherosclerosis was compared with direct intramuscular vector injection. Direct intramuscular vector injection results in 25 secretion of ApoA-I_{Milano} directly into the circulation.

For the transplants, ten million ApoE-/- bone marrow cells were transduced overnight (37 °C, IL-3 10 ng/ml, IL-6 10 ng/ml and SCF 1 ng/ml) with rAAV-ApoA-I_{Milano} at a multiplicity of infection (MOI) of 5000, washed (3X) and transplanted via the tail vein into 6-8 week old, lethally irradiated male Apo E-/- mice (1100 cGy, split dose).

30 For the intramuscular injections, 6-8 week old ApoE-/- mice were injected with 1-5x10¹² vector genomes/kg (2 X 50 µL in Gastrocnemeus muscle). A high fat diet was initiated three weeks after the bone marrow transplant and two weeks after the intramuscular

injection. Weight and retro-orbital bleeds were taken at two week intervals.

Approximately 20-24 weeks later, the aorta and large vessels extending from the aortic arch to femoral bifurcation were isolated, stained with oil red O, and the extent of atherosclerotic plaques were quantified. Negative controls included transplantation of

5 cells transduced with an irrelevant rAAV, untransduced transplants and unmanipulated mice. Positive controls included transplantation of wild type C57BL6/J bone marrow cells into irradiated ApoE-/- mice.

Although all ApoA-I_{Milano} treated groups showed marked reductions in plaque formation, transplantation with rAAV-ApoA-I_{Milano}-transduced marrow and intramuscular 10 injection of rAAV-ApoA-I_{Milano} resulted in a significant (approx. 50-60%) reduction in aortic atherosclerotic plaque formation as compared with controls. These results suggest that transplantation of rAAV-ApoA-1_{Milano} transduced multipotent stem cells and direct intramuscular injection may provide a novel and efficient strategy for controlling the development of atherosclerosis.

15

EXAMPLE 4

Long-term Inhibition of Atherogenesis Demonstrated in Animal Model by Intramuscular Injection or Transplantation of rAAV-Transduced Bone Marrow Cells

The effectiveness of rAAV vectors encoding ApoA-I_{Milano} for gene therapy of atherosclerosis *in vivo* was tested. In particular, the effectiveness of these vectors 20 following either intramuscular injection or transplantation of rAAV-transduced bone marrow cells was examined.

ApoE-/- mice were injected with approximately 10¹² vector genomes/kg at 6-8 weeks of age and placed on a high fat diet two weeks later. No major differences in body weight were observed between the treatment groups. 20-24 weeks after injection, 25 the mice were harvested, aortas were cleaned, fixed, mounted, stained with oil red O and atherosclerotic plaque areas quantified. Control untreated mice or mice treated with an irrelevant rAAV vector showed marked atherosclerotic lesion formation. In contrast, the rAAV-2-ApoA-I_{Milano} and rAAV-5-ApoA-I_{Milano} injected groups showed significant reductions in plaque formation, 58% and 50% respectively, despite a lack of 30 major differences in total plasma cholesterol levels.

Because marrow-derived monocytes and macrophages play a pivotal role in atherogenesis, it was hypothesized that transplantation of rAAV-ApoA-I_{Milano}-transduced marrow cells would also result in a decline in plaque formation, possibly due to the

localization of transduced macrophages within atherosclerotic lesions.

Lethally irradiated ApoE-/- mice were transplanted with rAAV transduced cells, and high fat diet was initiated two weeks later. Approximately 22 to 24 weeks after transplantation, the mice were euthanized, and aortas were analyzed for atherosclerotic plaques. Untransplanted mice, and mice transplanted with untransduced and control rAAV-transduced marrow served as negative controls. Wild type B6 to ApoE-/- transplants served as positive controls for plaque reduction. Results revealed a 47% and 49% reduction in atheroma formation following transplantation with marrow cells transduced with rAAV-2 and rAAV-5 vectors encoding ApoA-I_{Milano}, respectively.

These results suggest that intramuscular injection of rAAV-ApoA-I_{Milano} or transplantation of rAAV-transduced marrow cells results in significant long-term inhibition of atherogenesis following a single treatment with an rAAV vector.

EXAMPLE 5

Bone marrow transplant of rAAV-ApoA-I_{Milano}

Ten million ApoE-/- bone marrow cells were transduced overnight (37 °C, IL-3 10 ng/ml, IL-6 10 ng/ml and SCF 1 ng/ml) with rAAV-ApoA-I_{Milano} at a multiplicity of infection (MOI) of 5000, washed (3X) and transplanted via the tail vein into 6-8 week old, lethally irradiated male Apo E-/- mice (1100 cGy, split dose). A high fat diet was initiated three weeks after the procedures for all treatment groups. ApoE-/- mice transplanted with wild type marrow were used as a positive control for the experiment.

See Figure 13.

EXAMPLE 6

Intramuscular injection of rAAV-ApoA-I_{Milano}

For the intramuscular injections, 6-8 week old ApoE-/- mice were injected with 1-25 5x10¹² vector genomes/kg (2 X 50 µL in Gastrocnemeus muscle). A high fat diet was initiated two weeks after injection. See Figure 14.

While the description above refers to particular embodiments of the present invention, it will be understood that many modifications may be made without departing from the spirit thereof. For example, alternate methodologies and procedures well known to those of skill in the art may be substituted for the rAAV transduction procedure described in connection with the invention. Such alternate methodologies and procedures may be readily implemented without undue experimentation. The

presently disclosed embodiments are therefore to be considered in all respects as illustrative and not restrictive.

CLAIMS

WHAT IS CLAIMED IS:

1. A cell carrying a recombinant adeno-associated viral (rAAV) vector, further comprising an exogenous gene encoding Apolipoprotein A-I (ApoA-I),
5 ApoA-I_{Milano}, a fragment of ApoA-I or ApoA-I_{Milano}, or a derivative of ApoA-I or ApoA-I_{Milano}.
2. The cell of claim 1, wherein said exogenous gene is ApoA-I_{Milano}.
10
3. The cell of claim 1, wherein said rAAV vector is produced by the process of:
 - (i) providing a first plasmid that comprises said exogenous gene,
 - (ii) providing a second plasmid that is complementary to the first plasmid and which comprises components for rescue and packaging,
 - 15 (iii) co-transfected the first and second plasmids into a host cell, and
 - (iv) generating a quantity of said rAAV vector from said co-transfected host cell,
wherein the pair of said first and second plasmids is selected such that said rAAV vector is targeted for delivery to a specific tissue type.
- 20 4. The cell of claim 3, wherein said second plasmid further comprises AAV rescue and packaging components derived from an AAV serotype selected from the group consisting of AAV1, AAV2, AAV5, AAV7, AAV8, AAV9, AAV10 and combinations thereof.
- 25 5. The cell of claim 1, wherein said cell is a stem cell.
6. The cell of claim 1, wherein said cell is a multipotent stem cell.
- 30 7. The cell of claim 1, wherein said cell is a bone marrow cell.
8. A recombinant adeno-associated viral (rAAV) vector, comprising an exogenous

gene encoding:

- (a) Apolipoprotein A-I (ApoA-I);
- (b) ApoA-I_{Milano};
- (c) A fragment of (a) or (b); or
- (d) A derivative of (a) or (b).

5

9. The vector of claim 8, wherein said exogenous gene is ApoA-I_{Milano}.

10. The vector of claim 8, wherein said rAAV vector is produced by the process of:

- (i) providing a first plasmid that comprises said exogenous gene,
- (ii) providing a second plasmid that is complementary to the first plasmid and which comprises components for rescue and packaging,
- (iii) co-transfected the first and second plasmids into a host cell, and
- (iv) generating a quantity of said rAAV vector from said co-transfected host cell,

15 wherein the pair of said first and second plasmids is selected such that said rAAV vector is targeted for delivery to a specific tissue type.

11. The vector of claim 10, wherein said second plasmid further comprises AAV 20 rescue and packaging components derived from an AAV serotype selected from the group consisting of AAV1, AAV2, AAV5, AAV7, AAV8, AAV9, AAV10 and combinations thereof.

12. A composition, comprising:
25 a recombinant adeno-associated viral (rAAV) vector, further including an exogenous gene encoding Apolipoprotein A-I (ApoA-I), ApoA-I_{Milano}, a fragment of ApoA-I or ApoA-I_{Milano}, or a derivative of ApoA-I or ApoA-I_{Milano}; and a carrier.

30 13. The composition of claim 12, wherein said vector is formulated for delivery to a mammal.

14. The composition of claim 12, wherein said exogenous gene is ApoA-I_{Milano}.

15. The composition of claim 12, wherein said rAAV vector is produced by the process of:

- (i) providing a first plasmid that comprises said exogenous gene,
- (ii) providing a second plasmid that is complementary to the first plasmid and which comprises components for rescue and packaging,
- (iii) co-transfected the first and second plasmids into a host cell, and
- (iv) generating a quantity of said rAAV vector from said co-transfected host cell,

wherein the pair of said first and second plasmids is selected such that said rAAV vector is targeted for delivery to a specific tissue type.

10

16. The composition of claim 15, wherein said second plasmid further comprises AAV rescue and packaging components derived from an AAV serotype selected from the group consisting of AAV1, AAV2, AAV5, AAV7, AAV8, AAV9, AAV10 and combinations thereof.

15

17. A method of treating a condition in a mammal, comprising:

20

providing a recombinant adeno-associated viral (rAAV) vector comprising an exogenous gene encoding Apolipoprotein A-I (ApoA-I), ApoA-I_{Milano}, a fragment of ApoA-I or ApoA-I_{Milano}, or a derivative of ApoA-I or ApoA-I_{Milano}; and delivering said rAAV vector to said mammal in an amount sufficient to treat said condition.

18. The method of claim 17, wherein said exogenous gene is ApoA-I_{Milano}.

25

19. The method of claim 17, wherein said rAAV vector is produced by the process of:

- (i) providing a first plasmid that comprises said exogenous gene,
- (ii) providing a second plasmid that is complementary to the first plasmid and which comprises components for rescue and packaging,
- (iii) co-transfected the first and second plasmids into a host cell, and
- (iv) generating a quantity of said rAAV vector from said co-transfected host cell,

30

wherein the pair of said first and second plasmids is selected such that

said rAAV vector is targeted for delivery to a specific tissue type.

20. The method of claim 19, wherein said second plasmid further comprises AAV rescue and packaging components derived from an AAV serotype selected from the group consisting of AAV1, AAV2, AAV5, AAV7, AAV8, AAV9, AAV10 and combinations thereof.
- 10 21. The method of claim 17, wherein said condition is selected from the group consisting of coronary heart disease, arterio-sclerosis, atherosclerosis, atherogenesis, vascular inflammation, release of cytokines or other secretory products at abnormal levels, suppression or aggravation of inflammatory or immunological response, and combinations thereof.
- 15 22. The method of claim 17, wherein said mammal is a human.
23. The method of claim 17, wherein said amount sufficient to treat said condition is from about 1×10^{10} vector genome/kg of said mammal to about 1×10^{14} vector genome/kg of said mammal.
- 20 24. The method of claim 17, wherein said vector is delivered to said mammal intramuscularly, intravenously, or both.
- 25 25. The method of claim 17, wherein providing said rAAV vector, further comprises transducing multipotent stem cells with a quantity of said rAAV vector, and delivering said rAAV vector further comprises transplanting said multipotent stem cells into said mammal.
26. The method of claim 25, wherein said cells are bone marrow cells.
- 30 27. A kit for the treatment of a disease condition in a mammal, comprising:
a volume of recombinant adeno-associated viral (rAAV) vector comprising an exogenous gene encoding Apolipoprotein A-I (ApoA-I), ApoA-I_{Milano}, a fragment of ApoA-I or ApoA-I_{Milano}, or a derivative of ApoA-I or ApoA-I_{Milano}; and instructions for the use of said volume of rAAV vector for treating a

condition in said mammal.

28. The kit of claim 27, wherein said exogenous gene is ApoA-I_{Milano}.
- 5 29. The kit of claim 27, wherein said rAAV vector is produced by the process of:
 - (i) providing a first plasmid that comprises said exogenous gene,
 - (ii) providing a second plasmid that is complementary to the first plasmid and which comprises components for rescue and packaging,
 - (iii) co-transfected the first and second plasmids into a host cell, and
 - 10 (iv) generating a quantity of said rAAV vector from said co-transfected host cell,
wherein the pair of said first and second plasmids is selected such that said rAAV vector is targeted for delivery to a specific tissue type.
- 15 30. The kit of claim 29, wherein said second plasmid further comprises AAV rescue and packaging components derived from an AAV serotype selected from the group consisting of AAV1, AAV2, AAV5, AAV7, AAV8, AAV9, AAV10 and combinations thereof.
- 20 31. The kit of claim 27, wherein said condition is selected from the group consisting of coronary heart disease, arterio-sclerosis, atherosclerosis, atherogenesis, vascular inflammation, release of cytokines or other secretory products at abnormal levels, suppression or aggravation of inflammatory or immunological response, and combinations thereof.
- 25 32. The kit of claim 27, wherein said mammal is a human.
33. The kit of claim 27, wherein said vector is transduced into multipotent stem cells.
- 30 34. The kit of claim 33, wherein said cells are bone marrow cells.
35. A method of preparing a rAAV vector, comprising:
 - (i) providing a first plasmid that comprises an exogenous gene encoding Apolipoprotein A-I (ApoA-I), ApoA-I_{Milano}, a fragment of ApoA-I or ApoA-I_{Milano}, or

a derivative of ApoA-I or ApoA-I_{Milano};

(ii) providing a second plasmid that is complementary to the first plasmid and which comprises components for rescue and packaging,

(iii) co-transfected the first and second plasmids into a host cell, and

5 (iv) generating a quantity of said rAAV vector from said co-transfected host cell,

wherein the pair of said first and second plasmids is selected such that said rAAV vector is targeted for delivery to a specific tissue type.



FIGURE 1**FIGURE 2**


FIGURE 3



FIGURE 4A**FIGURE 4B**



FIGURE 5A**FIGURE 5B**






FIGURE 6**FIGURE 7A****FIGURE 7B**

FIGURE 8A**FIGURE 8B**

7/15




FIGURE 9**FIGURE 10A****FIGURE 10B**








FIGURE 11A**FIGURE 11B**

FIGURE 12A**FIGURE 12B****FIGURE 12C**

10/15

FIGURE 13A**FIGURE 13B****FIGURE 13C****FIGURE 13D**

11/15


FIGURE 14A**FIGURE 14B****FIGURE 14C****FIGURE 14D**



FIGURE 15**FIGURE 16**



FIGURE 17**FIGURE 18**





FIGURE 19**FIGURE 20**

FIGURE 21**rAAV****FIGURE 22****rAAV-5****rAAV-2**